ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

17 سبتمبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03 سبتمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

01 أغسطس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

31 يوليو 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

09 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

12 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

11 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming June Conferences

29 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

17 مايو 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

15 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming May Conferences

02 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

15 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

11 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

03 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

08 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

22 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

08 فبراير 2024 16:02:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

08 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

03 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

12 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire